Delta-8 vs. Delta-9 THC in Blood Testing: Can the Method Separate the Isomers?

Delta-8 THC and delta-9 THC have the same molecular formula and molecular weight. They are constitutional isomers: the same atoms are connected differently because the carbon-carbon double bond occupies a different position.

That small structural difference creates a large analytical question. If a laboratory method does not adequately separate the compounds before mass-spectrometric detection, a delta-8 THC signal can overlap with delta-9 THC. The same problem can affect their carboxy metabolites.

A toxicology report may therefore raise two different questions:

1. Did the instrument produce ions associated with a THC compound?
2. Did the complete method reliably distinguish the specific isomer being reported?

The first question does not automatically answer the second.

Why mass transitions are not enough

Liquid chromatography-tandem mass spectrometry identifies compounds through a combination of chromatographic retention and mass-spectrometric behavior. Multiple-reaction-monitoring transitions can be highly selective, but constitutional isomers may produce the same precursor and product ions.

When delta-8 and delta-9 THC share monitored transitions, the chromatographic separation carries the burden of distinguishing them. If the peaks overlap, the detector may see both compounds while the data system cannot reliably assign the signal to one isomer.

This is why an LC-MS/MS label does not, by itself, establish isomer specificity. The column chemistry, mobile phase, gradient, temperature, run time, retention-time criteria, ion ratios, peak shape, and integration rules all matter.

For method background, see Liquid Chromatography-Tandem Mass Spectrometry, Chromatography in Toxicology, and Mass Spectrometry in Toxicology.

What the published DUID casework study found

Chan-Hosokawa and colleagues reported an increasing number of unresolved cannabinoid confirmations in blood specimens from driving-under-the-influence-of-drugs investigations. Their preexisting two-dimensional LC-MS/MS procedure showed overlapping peaks affecting delta-9 THC and delta-9 carboxy-THC. The laboratory's canceled-testing rate attributed to the interfering substances reached 3.7 percent in February 2019.

The investigators connected the interference pattern to delta-8 THC and delta-8 carboxy-THC. They then developed and validated a longer, ten-minute two-dimensional LC method intended to resolve the delta-8 and delta-9 parent compounds and metabolites.

The reported lower limits of quantitation for the delta-9 analytes remained the same as in the laboratory's original method: 0.5 ng/mL for delta-9 THC, 1.0 ng/mL for 11-hydroxy-delta-9 THC, and 5.0 ng/mL for delta-9 carboxy-THC. Under the study conditions, the longer method separated the relevant isomer pairs.

That result is important because it demonstrates a real casework problem, not merely a theoretical possibility. It also demonstrates that a laboratory can discover an interference after a method has already been placed into service.

A second validated method found the same practical problem

Reber and colleagues later reported another validated LC-MS/MS method for separating delta-8 and delta-9 THC and their carboxy metabolites in blood and urine. The method used solid-phase extraction, a multistep liquid-chromatography gradient, and tandem mass spectrometry. Its validation addressed selectivity, calibration, detection and quantitation limits, bias, precision, matrix effects, stability, dilution integrity, and carryover under ANSI/ASB Standard 036.

The method achieved quantitative results for delta-8 and delta-9 parent THC in blood, with a reported lower limit of quantitation of 1 microgram per liter. It could detect the delta-8 and delta-9 carboxy metabolites at 5 micrograms per liter in blood and urine, but those metabolites were reported qualitatively rather than quantitatively.

That reporting distinction was not cosmetic. Delta-8-THCCOOH showed unacceptable bias in some validation experiments because of matrix effects. At the time of development, a matching deuterated delta-8-THCCOOH internal standard was not available. The authors limited the reported conclusion instead of claiming numerical accuracy their data did not support.

The authentic cases also showed why isomer separation changes case interpretation. Two blood cases contained delta-8 THC and delta-8-THCCOOH without corresponding reportable delta-9 compounds. Another comparison showed that the laboratory's older method had assigned a delta-8 peak to delta-9 THC before the improved chromatographic separation resolved the isomers correctly.

The two studies used different instruments and chromatographic strategies, but they reached the same operational point: shared mass transitions do not identify the positional isomer. The laboratory must demonstrate adequate chromatographic separation in the method actually used on the specimen.

A canceled or inconclusive result is information

The original laboratory did not simply assign an overlapping signal to delta-9 THC. It canceled testing when the method could not resolve the interference. That decision protected the report from a potentially unsupported identification.

An inconclusive result does not establish that the evidence was negative. It means the method did not support the requested conclusion under the laboratory's identification rules. A later method may resolve the same specimen, but the later analysis must be documented and reviewed on its own terms.

The distinction matters in case review. A reviewer should determine whether the laboratory:

• Recognized the interference
• Reintegrated or manually changed the peak
• Reanalyzed the specimen with a different method
• Used reference materials for both isomers
• Reported one compound, both compounds, or an inconclusive result
• Changed its method or reporting policy after the test date

For related issues, see Analytical Interferences and Chromatogram Integration.

What proper isomer-separation validation should show

A validation should challenge the specific compounds that the method may encounter. Testing delta-9 THC alone does not demonstrate separation from delta-8 THC. The same principle applies to the delta-8 and delta-9 carboxy metabolites.

Relevant validation experiments include:

• Separate injections of certified delta-8 and delta-9 reference materials
• Mixtures containing both isomers at equal and unequal concentrations
• Concentrations near the reporting limit and near the upper analytical range
• Interference challenges in authentic or representative whole-blood matrix
• Retention-time windows established from adequate data
• Ion-ratio performance when one isomer is much more abundant than the other
• Carryover, matrix-effect, recovery, and processed-sample-stability studies
• Reproducibility across analysts, instruments, columns, and reagent lots
• Peak-resolution acceptance criteria defined before casework interpretation

The validation should document what happens when the isomers are not baseline separated. A laboratory needs a decision rule for partial overlap, shoulders, distorted peak shape, retention drift, and integration disagreement.

See Forensic Toxicology Method Validation, Quality and Validation, and Method Transfer in Toxicology.

Records needed for a case-specific review

The final report is not enough to determine whether the isomer assignment was analytically justified. A meaningful review should request:

1. The complete method and version used on the date of testing.
2. The validation study, including delta-8/delta-9 resolution data.
3. The original and reintegrated chromatograms for the specimen.
4. Calibrator, quality-control, blank, and internal-standard chromatograms from the batch.
5. Quantifier and qualifier transitions and the acceptance limits for ion ratios.
6. Retention times and permitted retention-time windows.
7. Peak-resolution calculations or other predefined separation criteria.
8. The identity, lot, concentration, and certificates for reference materials.
9. Instrument maintenance, column history, and sequence information.
10. Audit trails showing manual integration or reprocessing.
11. Corrective-action records concerning cannabinoid isomer interference.
12. Any later method revision adopted to address delta-8 THC.

These records allow the reviewer to reconstruct what the method actually did. A statement that the assay was "validated" is a conclusion; the validation data are the evidence.

Identification is not impairment

Even a correctly identified and accurately measured delta-8 or delta-9 THC concentration does not resolve every forensic question. Analytical identification addresses what compound was present in the specimen. Impairment is a separate opinion involving timing, pharmacology, tolerance, observed behavior, driving evidence, other substances, and the limits of the available research.

The Chan-Hosokawa paper is principally an analytical-method study. It does not establish a blood-concentration threshold at which delta-8 THC or delta-9 THC proves driving impairment.

For related interpretation, see Cannabis Metabolites in Toxicology and Whole Blood vs. Plasma Toxicology.

The bottom line

When constitutional isomers share mass transitions, the chromatographic separation is part of the identification. A laboratory cannot solve an unresolved peak by pointing to the mass spectrometer alone.

The decisive questions are practical: Were delta-8 and delta-9 THC both included in the validation? Did the method separate them at the concentrations present? What did the original chromatograms show? Were the integration and identification rules followed?

The name printed on a toxicology report is only as specific as the complete method that produced it.

Primary source

Chan-Hosokawa A, Nguyen L, Lattanzio N, Adams WR. Emergence of Delta-8 Tetrahydrocannabinol in DUID Investigation Casework: Method Development, Validation and Application. Journal of Analytical Toxicology. 2022;46(1):1-9. Oxford Academic journal record. doi:10.1093/jat/bkab029.

Reber JD, Karschner EL, Seither JZ, Knittel JL, Dozier KV, Walterscheid JP. An Enhanced LC-MS-MS Technique for Distinguishing Delta-8- and Delta-9-Tetrahydrocannabinol Isomers in Blood and Urine Specimens. Journal of Analytical Toxicology. 2022;46(4):343-349. PubMed record. doi:10.1093/jat/bkac007.

For a broader framework for interpreting cannabinoid evidence, see Cannabis & THC Forensic Toxicology.

Editorial note: This article paraphrases the published study. Do not upload or reproduce the source PDF, publisher layout, figures, tables, or substantial verbatim text.